Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Complete or partial reversal of opioid depression including respiratory depression; diagnosis of suspected or known acute opioid overdosage; as an adjunctive agent to increase blood pressure in the management of septic shock; reversal of opioid sedation after anaesthesia; Reversal of sedation and respiratory depression in neonate after maternal exposure to opioids.
Adult: Initial dose of 0.4-2mg, IV [or IM or SC when IV is not available]. If the desired effects are not attained repeat at 2-3 minute interval [up to 10mg]. Children & neonates: 0.01 mg/kg I.V. A subsequent dose of 0.1 mg/kg may be administered if the response is not satisfactory.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.